<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162929</url>
  </required_header>
  <id_info>
    <org_study_id>CTA-Control-092517</org_study_id>
    <nct_id>NCT00162929</nct_id>
  </id_info>
  <brief_title>Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)</brief_title>
  <acronym>AdHERe</acronym>
  <official_title>A Phase I Study Investigating Multiple Injections of Autologous CD34+ Derived Dendritic Cells Transduced With an Adenovirus Expressing Rat Her-2/Neu in Patients With Metastatic or Locally Recurrent Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Breast Cancer Research Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose and/or maximum
      attainable dose of a vaccine consisting of human autologous dendritic cells transduced by an
      adenovector expressing rat Her-2/neu (AdHer-2/neu) in patients with metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicity</measure>
    <time_frame>weeks 4, 6, 7, 10, 14, 18, 22, 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumour response</measure>
    <time_frame>Weeks 6, 18</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdHer-2/neu transduced dendritic cells</intervention_name>
    <description>Group 1 1 ×10'7 expanded cells (2.5 ×106 DCs per injection site) Group 2 5 ×10'7 expanded cells (1.25 ×107 DCs per injection site) Group 3 1 ×10'8 expanded cells (2.5 ×107 DCs per injection site)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Metastatic or locally recurrent breast cancer

          2. 18 years of age or older

          3. Her-2/neu positive (3+ by immunohistochemistry or fluorescence in-situ hybridization
             [FISH] +)

          4. One of the following:

               1. currently receiving hormonal therapy or are candidates for such, or

               2. being considered for trastuzumab, or

               3. cancer has progressed on trastuzumab.

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Prior or concurrent malignancies except for treated basal cell or squamous cell
             carcinoma of the skin or in situ cancer of the cervix or any other cancer treated and
             presumed cured for more than five years prior to study entry.

          3. Currently receiving chemotherapy, immunotherapy, adenoviral gene therapy or biological
             cancer therapy. [Note: concurrent hormonal therapy (tamoxifen, aromatase inhibitors,
             or megace) is permitted.]

          4. Treatment with trastuzumab within 4 weeks prior to first dose of vaccine therapy.

          5. Hemoglobin &lt; 80 g/L or granulocytes &lt; 1.5 × 10^9/L or lymphocytes &lt; 1.0 × 10^9/L or
             platelets &lt; 100 × 10^9/L.

          6. Baseline liver enzymes (AST or ALT) greater than 3 times the upper limit of normal or
             greater than 5 times the upper limit of normal if liver metastases are present and/or
             bilirubin is greater than 50 mmol.

          7. CD4 cells &lt; 0.5 ×10^9/L

          8. Patients with documented brain metastases.

          9. Patients with any acute illness that would interfere with the collection of CD34+
             cells or administration of vaccination cellular therapy (i.e. unstable angina, renal
             or liver failure, or severe chronic obstructive airway disease).

         10. Any patients requiring concurrent immunosuppressive therapy (e.g. corticosteroids).

         11. Eastern Cooperative Oncology Group (ECOG) performance status of &gt; 2.

         12. Patients with a life expectancy of less than 6 months.

         13. Geographic inaccessibility which would preclude follow-up. Patients registered on the
             trial must be treated and followed at the Juravinski Cancer Center and the Henderson
             site of the Hamilton Health Sciences.

         14. Failure to give written informed consent.

         15. Baseline left ventricular ejection fraction (LVEF) &lt; 55% by echocardiography or
             multigated acquisition (MUGA) scan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sukhbinder Dhesy-Thind, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Ontario Clinical Oncology Group; Juravinski Cancer Centre - Hamilton Health Sciences; McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronan Foley, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Tozer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juravinski Cancer Centre - Hamilton Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Ellis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juravinski Cancer Centre - Hamilton Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jack Gauldie, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Levine, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>locally recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

